-
公开(公告)号：US20230027238A1
公开(公告)日：2023-01-26
申请号：US17781639
申请日：2020-12-04
Applicant: Spectrum Pharmaceuticals, Inc.
Inventor： Shanta Chawla , Gajanan Bhat
IPC: A61K47/68 , A61K47/60 , A61P7/00 , A61K31/337 , A61K31/664
Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.
-
公开(公告)号：US20160287660A1
公开(公告)日：2016-10-06
申请号：US15061821
申请日：2016-03-04
Applicant: Spectrum Pharmaceuticals Inc.
Inventor： Anthony W. Tolcher , Luigi Lenaz
IPC: A61K38/10 , A61K31/337
CPC classification number: A61K38/10 , A61K31/337
Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
-
公开(公告)号：US09295666B2
公开(公告)日：2016-03-29
申请号：US14015829
申请日：2013-08-30
Applicant: Spectrum Pharmaceuticals, Inc.
Inventor： Bastiaan Nuijen , Ernie Pfadenhauer , Jos H. Beijnen , Dorla Mirejovsky , Guru Reddy , Luigi Lenaz
CPC classification number: A61K31/404 , A61K9/0019 , A61K9/0034 , A61K9/08 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/26
Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
-
公开(公告)号：US20160008396A1
公开(公告)日：2016-01-14
申请号：US14860023
申请日：2015-09-21
Applicant: Spectrum Pharmaceuticals, Inc.
Inventor： Rudi E. Moerck , Timothy Malcome Spitler , Edward A. Schauer , Jan Prochazka
CPC classification number: A61K33/24 , A61K9/0053 , A61K9/16 , A61K9/1611 , B01J20/0207 , B01J20/0211 , B01J20/0277 , B01J20/0288 , B01J20/06 , B01J20/28057 , B01J20/3234 , B01J20/3236 , C01F17/005 , C01F17/0068 , C01P2002/60 , C01P2002/72 , C01P2004/03 , C01P2004/61 , C01P2004/80 , C01P2006/12 , C01P2006/14 , C01P2006/90 , C02F1/001 , C02F1/281 , C02F2101/103 , C02F2101/105 , C02F2101/20 , C02F2103/026 , C09C1/3661 , Y10T428/2982
Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
-
5.发明授权Sensitization of tumor cells to radiation therapy through administration of endothelin agonists 有权通过给予内皮素激动剂使肿瘤细胞对放射治疗敏感公开(公告)号：US08957014B2
公开(公告)日：2015-02-17
申请号：US13761043
申请日：2013-02-06
Inventor： Anil Gulati , Guru Reddy , Luigi Lenaz
IPC: A61K38/00 , A61N5/00 , A61K41/00 , A61K31/00 , A61K31/28 , A61K31/337 , A61K31/4745 , A61K31/519 , A61K31/704 , A61K33/24 , A61K38/17 , A61K38/22 , A61K45/06 , A61N5/10
CPC classification number: A61K41/0038 , A61K31/00 , A61K31/28 , A61K31/337 , A61K31/4745 , A61K31/519 , A61K31/704 , A61K33/24 , A61K38/1703 , A61K38/2285 , A61K45/06 , A61N5/00 , A61N2005/1098 , A61K2300/00
Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
Abstract translation: 通过施用内皮素激动剂如ETB激动剂IRL1620使肿瘤细胞对放射治疗敏感的方法。
-
Patent Agency Ranking
公开(公告)号：US20150004086A1
公开(公告)日：2015-01-01
申请号：US14491305
申请日：2014-09-19
Applicant: SPECTRUM PHARMACEUTICALS, INC.
Inventor： Rudi E. Moerck , Timothy Malcome Spitler , Edward A. Schauer , Jan Prochazka
CPC classification number: A61K33/24 , A61K9/0053 , A61K9/16 , A61K9/1611 , B01J20/0207 , B01J20/0211 , B01J20/0277 , B01J20/0288 , B01J20/06 , B01J20/28057 , B01J20/3234 , B01J20/3236 , C01F17/005 , C01F17/0068 , C01P2002/60 , C01P2002/72 , C01P2004/03 , C01P2004/61 , C01P2004/80 , C01P2006/12 , C01P2006/14 , C01P2006/90 , C02F1/001 , C02F1/281 , C02F2101/103 , C02F2101/105 , C02F2101/20 , C02F2103/026 , C09C1/3661 , Y10T428/2982
Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
-
7.发明授权公开(公告)号：US08729023B2
公开(公告)日：2014-05-20
申请号：US13711519
申请日：2012-12-11
Inventor： Anil Gulati , Guru Reddy , Luigi Lenaz
CPC classification number: A61K38/10 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/704 , A61K31/7072 , A61K38/2013 , A61K38/21 , A61K38/2285 , A61K45/06 , A61K2300/00
Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
Abstract translation: 公开了用于治疗癌症（包括实体瘤）的方法，组合物和制品。 方法，组合物和制品可以利用内皮素B激动剂（ETB）来增强化疗剂的递送和产生的功效。
-
8.发明申请公开(公告)号：US20210260064A1
公开(公告)日：2021-08-26
申请号：US17250259
申请日：2019-06-25
Inventor： Guru Reddy , Sunyoung Jang , Jooyun Byun
IPC: A61K31/517 , A61K39/395 , A61K31/337 , A61K33/243 , A61K31/513 , A61K31/395 , A61K31/537 , A61K47/68 , A61K9/00 , A61P35/00
Abstract: Provided are combinations of poziotinib and an anti-HER1, anti-HER2 or anti-HER4 antibody, optionally with other agents, and use of the combinations for treating cancer.
-
公开(公告)号：US20200261455A1
公开(公告)日：2020-08-20
申请号：US16757072
申请日：2018-10-18
Applicant: Spectrum Pharmaceuticals, Inc.
Inventor： Prasad V. Chaturvedual , Prasad Kolli
IPC: A61K31/517 , A61K31/506 , A61K31/69
Abstract: An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.
-
公开(公告)号：US20180177783A1
公开(公告)日：2018-06-28
申请号：US15736550
申请日：2016-06-14
Applicant: Spectrum Pharmaceuticals, Inc.
Inventor： Guru Reddy
IPC: A61K31/519 , A61K31/18 , A61K31/714 , A61P35/00
CPC classification number: A61K31/519 , A61K31/18 , A61K31/714 , A61K45/06 , A61P35/00 , A61K2300/00
Abstract: The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.031 seconds)
